# Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Source: https://onco.cc/trials/nct05573126/  
OnCo record `nct05573126` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Ellipses Pharma, now recruiting.

## Summary

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT05573126 by Ellipses Pharma, with 95 participants planned, started 2023-01-11 and due to reach its primary completion in 2028-02. Interventions recorded: EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05573126
- Phase: 1/2
- Setting: A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Sponsor: Ellipses Pharma
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05573126: https://clinicaltrials.gov/study/NCT05573126

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Elacestrant](https://onco.cc/drugs/elacestrant/), [EP0062](https://onco.cc/drugs/ep0062/), [Everolimus](https://onco.cc/drugs/everolimus/), [Exemestane](https://onco.cc/drugs/exemestane/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05573126.json